Analysts Set Arbutus Biopharma (ABUS) Price Target at $12.38

Shares of Arbutus Biopharma (NASDAQ:ABUS) have received an average rating of “Hold” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $12.38.

A number of research firms recently issued reports on ABUS. BidaskClub lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, February 3rd. B. Riley initiated coverage on shares of Arbutus Biopharma in a research report on Friday, January 5th. They issued a “buy” rating and a $10.00 price objective for the company. ValuEngine upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, March 15th. Zacks Investment Research upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, March 22nd. Finally, Chardan Capital initiated coverage on shares of Arbutus Biopharma in a research report on Monday, March 19th. They issued a “buy” rating and a $8.25 price objective for the company.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ ABUS traded down $0.15 during midday trading on Thursday, reaching $5.10. 334,970 shares of the company were exchanged, compared to its average volume of 180,567. The company has a quick ratio of 8.85, a current ratio of 8.85 and a debt-to-equity ratio of 0.09. Arbutus Biopharma has a 1 year low of $3.20 and a 1 year high of $8.25. The firm has a market cap of $291.87, a P/E ratio of -2.85 and a beta of 1.06.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.51). Arbutus Biopharma had a negative return on equity of 55.28% and a negative net margin of 796.23%. The company had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $0.70 million. analysts anticipate that Arbutus Biopharma will post -1.7 earnings per share for the current year.

Large investors have recently made changes to their positions in the stock. Point72 Asset Management L.P. acquired a new stake in Arbutus Biopharma in the third quarter valued at about $1,393,000. RTW Investments LP lifted its position in Arbutus Biopharma by 1.1% in the third quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after purchasing an additional 56,457 shares during the period. Hudson Bay Capital Management LP lifted its position in Arbutus Biopharma by 239.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 400,000 shares of the biopharmaceutical company’s stock valued at $2,020,000 after purchasing an additional 282,000 shares during the period. Victory Capital Management Inc. lifted its position in Arbutus Biopharma by 16.6% in the fourth quarter. Victory Capital Management Inc. now owns 150,720 shares of the biopharmaceutical company’s stock valued at $761,000 after purchasing an additional 21,460 shares during the period. Finally, OxFORD Asset Management LLP lifted its position in Arbutus Biopharma by 49.2% in the third quarter. OxFORD Asset Management LLP now owns 124,273 shares of the biopharmaceutical company’s stock valued at $778,000 after purchasing an additional 40,963 shares during the period. Hedge funds and other institutional investors own 62.12% of the company’s stock.

WARNING: This news story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://weekherald.com/2018/04/19/analysts-set-arbutus-biopharma-abus-price-target-at-12-38.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply